• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2024)

October 15 - 18, 2024

  1. gMG
  2. NMOSD

pdf

Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: a retrospective analysis of registry data

pdf

Concomitant corticosteroid use with ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: phase 3 CHAMPION-MG open-label extension final results

pdf

Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with gMG or NMOSD: an analysis of US clinical practice

pdf

Long-term corticosteroid treatment patterns and steroid-sparing effects of approved treatments for generalized myasthenia gravis in the United States

pdf

Outcomes for patients with generalized myasthenia gravis prescribed ravulizumab, eculizumab, or efgartigimod treatment: interim analysis of a retrospective medical record analysis (ELEVATE)

pdf

Patient preferences for generalized myasthenia gravis treatment profiles: results of a web-based survey

pdf

Quality of life in generalised myasthenia gravis: results from a global registry of eculizumab and ravulizumab treatment

pdf

Safety and effectiveness of ravulizumab in generalised myasthenia gravis: evidence from a global registry

pdf

Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with gMG or NMOSD: an analysis of US clinical practice

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice